Mirena generic
Mirena is an intrauterine device owned by Bayer Healthcare. The active ingredient in Mirena is levonorgestrel. It was first authorized for market use on 06 December, 2000, and currently, it holds a total of 4 patents, none of which have expired.
When will Mirena generic be available?
The patents protecting Mirena from generic competition are set to expire over the course of the next decade. The final patent, U.S. Patent No. 10987244, titled 'Inserter', is due to expire on April 1, 2031. Therefore, Mirena generic could potentially be available after this date.
Mirena uses
Mirena is used as a contraceptive method by positioning an intrauterine system (IUS) inside the uterus. This involves determining the depth of the uterus, holding an inserter handle with one hand, inserting the IUS into the uterus, and retracting a slider on the handle to release the IUS. The active ingredient, levonorgestrel, makes it effective by preventing ovulation and altering the lining of the uterus to prevent pregnancy.
Mirena patent expiration
Mirena holds a total of 4 patents, the last of which, titled 'Inserter', expires on April 1, 2031. Only after this date, a Mirena generic version could be released. Below is the detail of the patent: